Clear Clinical Demand: Existing treatment regimens fail to fully address cardiovascular risks caused by inflammation.
Mechanism Innovation: Breaking traditional lipid-lowering approaches to directly target the root cause of vascular inflammation.
Proven Efficacy: Further reduce the risk of cardiovascular events by nearly one-third.
High Safety Profile: Adverse reaction incidence ≤ 10%, suitable for long-term administration.
——The first FDA-approved anti-inflammatory drug for the treatment of cardiovascular diseases
Clinical Value
Applicable Population
Adult patients diagnosed with atherosclerotic cardiovascular disease (ASCVD) High-risk populations with multiple cardiovascular risk factors Patients with residual inflammatory risk despite standard statin and antiplatelet therapy
Indications
It is indicated to reduce the risks of myocardial infarction, stroke, coronary revascularization and cardiovascular death in adult patients with confirmed atherosclerotic disease or multiple cardiovascular disease risk factors.
